Brief: MaxCyte Q4 Revenue USD 8.7 Million Vs. IBES Estimate USD 7.93 Million
11/03/2025 20:05
Mar 11 (Reuters) - MaxCyte Q4 adjusted EBITDA USD -11.8 million. Q4 gross profit USD 6.4 million Q4 operating expenses USD 19.3 million Q4 net income USD -10.6 million
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026